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The essential mitotic kinase Aurora A (AURKA) is controlled during cell cycle progression via two 
distinct mechanisms. Following activation loop autophosphorylation early in mitosis when it localizes 
to centrosomes, AURKA is allosterically activated on the mitotic spindle via binding to the microtubule-
associated protein, TPX2. Here, we report the discovery of AurkinA, a novel chemical inhibitor of the 
AURKA-TPX2 interaction, which acts via an unexpected structural mechanism to inhibit AURKA activity 
and mitotic localization. In crystal structures, AurkinA binds to a hydrophobic pocket (the ‘Y pocket’) 
that normally accommodates a conserved Tyr-Ser-Tyr motif from TPX2, blocking the AURKA-TPX2 
interaction. AurkinA binding to the Y- pocket induces structural changes in AURKA that inhibit catalytic 
activity in vitro and in cells, without affecting ATP binding to the active site, defining a novel mechanism 
of allosteric inhibition. Consistent with this mechanism, cells exposed to AurkinA mislocalise AURKA 
from mitotic spindle microtubules. Thus, our findings provide fresh insight into the catalytic mechanism 
of AURKA, and identify a key structural feature as the target for a new class of dual-mode AURKA 
inhibitors, with implications for the chemical biology and selective therapeutic targeting of structurally 
related kinases.
Aurora A kinase (AURKA) is a member of a family of Ser/Thr kinases whose orthologues control progression 
through mitotic cell division1,2. The Aurora family is evolutionarily conserved and three known human mem-
bers of this family, Aurora A, Aurora B and Aurora C, bear sequence homology to those found in yeast and 
Drosophila3–5. The human Aurora kinases share a relatively conserved kinase catalytic domain at the carboxy-(C) 
terminus, but a small sequence variation within this domain contributes to the different spatio-temporal localiza-
tion of the Aurora kinases during the cell cycle, leading to their distinct cellular functions6–9.
In particular, AURKA has been implicated in multiple events accompanying transit through the G2 to M 
phases of the cell cycle, and during mitotic cell division. These include centrosome multiplication10,11 and matura-
tion12–15, bipolar spindle formation16–18, stability and function19–21. Indeed, while interphase cells contain a signif-
icant cytoplasmic pool of AURKA22,23, the kinase localises to distinct structures during cell cycle progression24–26. 
In late G2 phase, AURKA begins to accumulate at centrosomes, where it interacts with and is activated by numer-
ous binding partners, such as Ajuba27,28, Arpc1b29,30, calmodulin31,32, CEP19210,33, NEDD934 and nucleophosmin 
B2335. The centrosomal activation of AURKA is essential for pericentriolar material (PCM) accumulation and 
bipolar spindle formation. During prophase and metaphase, AURKA is recruited to the spindle microtubules, a 
less well-studied event essential for establishment of correct spindle length10. Upon anaphase onset, most AURKA 
is rapidly degraded by APC/C complex such that by the end of cytokinesis AURKA is largely undetectable36.
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The localisation of AURKA to microtubules in the mitotic spindle is mediated through its interaction with a 
protein partner, TPX227. The AURKA-TPX2 interaction involves the first 43 N-terminal amino acids of TPX2, 
which bind to the C-terminal catalytic lobe of AURKA. Crucially, mutation of three residues within this 43 amino 
acid stretch (Y8, Y10 and D11) abolishes the ability of TPX2 to bind AURKA, and leads to mitotic defects10. 
Besides localisation, the AURKA-TPX2 interaction modulates the catalytic activity of AURKA37,38. Recent struc-
tural and biological evidence separates the potential contributions towards AURKA activation made by activation 
loop auto-phosphorylation and TPX2-induced allosteric activation24. Upon binding, TPX2 induces an active con-
formation of AURKA as defined by internal hallmarks of active kinases: notably, the formation of a Lys-Glu salt 
bridge within the N-lobe, and hydrophobic spine alignment39. While the auto-phosphorylation of Thr288 of the 
activation loop results in a similar conformation, the TPX2 binding additionally protects the key phosphorylated 
Thr288 from solvent exposure and thus its accessibility to protein phosphatases38,40. The auto-phosphorylation 
appears to be essential in activating AURKA in the centrosomes at early stages in mitosis, and the allosteric acti-
vation by TPX2 of dephosphorylated AURKA may be critical during spindle formation.
Over-expression of AURKA occurs frequently in a range of human cancers41, inspiring attempts to therapeuti-
cally target its activity using ATP-competitive inhibitors now being tested in clinical trials42. These inhibitors have 
also proven invaluable for chemical biology studies of AURKA function43–45. However, ATP-competitive inhibi-
tors are well known for exhibiting various levels of promiscuity46, prompting interest in the allosteric inhibition 
of AURKA by compounds that disrupt its interaction with the activator TPX2.
Here, we report the identification of AurkinA, a drug-like inhibitor of AURKA, which binds to a pocket occu-
pied by Y8 and Y10 of TPX2 in the AURKA-TPX2 complex (the Y-pocket). AurkinA disrupts the AURKA-TPX2 
interaction in vitro, and mislocalises the kinase from the mitotic spindle in cells. Unexpectedly, the binding of 
AurkinA to the Y-pocket leads to conformational alterations in AURKA distinct from those induced by TPX2 
binding, restricting activation loop stabilization, and inhibiting catalytic activity via an allosteric mechanism. 
These alterations inhibit enzymatic activity in vitro and in vivo, but do not alter AURKA’s affinity for ATP, sug-
gesting a novel mode of enzyme inhibition. Thus, our findings provide insight into the catalytic mechanism of 
AURKA, and provide a blueprint for the design of selective small-molecule inhibitors that target its Y-pocket, 
exemplifying a new allosteric approach for the dual-mode inhibition of AURKA localisation and activity.
Results
Identification and chemical optimisation of an Aurora-A-TPX2 inhibitor. We embarked on a high 
throughput screening (HTS) campaign using a library of 17000 rationally-selected compounds47 to identify 
compounds capable of disrupting the interaction between the AURKA catalytic domain and TPX2. We used a 
fluorescence anisotropy (FA) assay in which we measured the binding between a truncated recombinant His-
tagged form of AURKA123–403 and a TAMRA-labelled TPX2 peptide fragment consisting of amino acids 1–43. The 
dose-dependent binding of the two components (Fig. 1a) allowed us to develop a statistically robust FA assay for 
screening (Supplementary Fig. 1).
The screen identified 15 potential inhibitors of the AURKA-TPX2 protein:protein interaction (PPI), resulting 
in hit rate of 0.09%. The HTS actives were resupplied and retested to check for dose-dependent inhibition of the 
PPI in FA assay. To remove the actives that bound to the ATP site of Aurora A and potentially allosterically inhib-
ited the AURKA-TPX2 interaction, we performed a second round of the FA assay, with the addition of excess 
JNJ-7706621 (JNJ), a potent non-selective ATP-competitive Aurora A inhibitor48. JNJ did not interfere with the 
AURKA-TPX2 binding, and helped to stabilize AURKA protein (Supplementary Fig. 1). By comparing the activ-
ity of HTS hits in FA assay in presence or absence of the ATP site-blocking JNJ compound, we identified several 
compounds that were not significantly displaced by JNJ, suggesting they did not engage the ATP-site of AURKA 
(Supplementary Fig. 2). The most promising of these was 1 (Fig. 1c), which we chose to focus on.
The HTS hit 1 inhibited the AURKA:TPX2 interaction in a dose-dependent manner with an IC50 value of 41 μ M 
(Fig. 1b). We further confirmed the direct binding of 1 to AURKA by isothermal titration calorimetry (ITC) 
(Supplementary Fig. 3). The ITC indicated that 1 bound to AURKA with a 1:1 stoichiometry, with binding affinity 
in the low micromolar range (Kd = 10.6 μ M, pKd = 4.98 ± 0.03). The direct binding affinity value was in agree-
ment with the Ki value calculated from competitive FA assay (Ki = 8.9 μ M) using the free-concentration corrected 
Cheng-Prusov equations49.
Fragment-based drug discovery has proved to be a useful tool in developing PPI inhibitors, permitting access 
to ligand-efficient hit elaboration campaigns1,2. With this in mind, we split 1 into constituent fragments, a process 
we refer to as fragment deconstruction (Fig. 1c). This yielded two simple fragments: 2 amino-benzoic acid, and 
3, 2-phenyl-4-carboxyquinoline, which is also known as cincophen, an approved veterinary drug used for the 
treatment of arthritis in animals. Unlike 2, compound 3 caused a dose-dependent inhibition of TPX2 binding to 
AURKA in the FA assay (IC50 = 63 μ M, Fig. 1b), suggesting that this was the critical part of the molecule that was 
responsible for the binding of H1 to AURKA.
Accordingly, we synthesised new fragments exploring the structure-activity relationship (SAR) around the 
cinchophen moiety. Testing of the new set of elaborated fragments in the FA assay (Supplementary Table 1) 
revealed a number of SAR trends. Increasing hydrophobicity of the phenyl group increased potency in the FA 
assay, and introduction of a hydrophobic group, such as F, Cl, CF3 or Br at the meta position was particularly 
favourable. Interestingly, an isoquinoline variant of 3, generated by moving the nitrogen, was poorly toler-
ated in the assay. This SAR insight allowed us to optimise the compound structure by iterative fragment syn-
thesis and FA assay testing to yield AurkinA, a potent, binding-efficient, low-molecular weight inhibitor of the 
AURKA:TPX2 interaction (Fig. 1c). We determined the binding affinity of AurkinA to AURKA to be 3.77 μ M 
(pKd = 5.42 ± 0.03) by ITC (Supplementary Fig. 4), in line with its IC50 value in the FA assay. The stoichiometric 
association of AurkinA to AURKA was driven by enthalpy (∆ H = − 23.1 kcal/mol) and the binding was entrop-
ically disfavoured (-T∆ S = 15.7 kcal/mol). The thermodynamic signature was consistent with an induction of a 
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significant conformational change in protein structure upon the AurkinA binding3–5. The ligand efficiency of 
AurkinA was 0.36, which is considered to be a good metric for an early stage hit compound and on par with much 
smaller fragments, suggesting potential for further development6–9.
AurkinA binds to a hydrophobic pocket in AURKA. To provide structural insight into how AurkinA 
binding might hinder formation of the AURKA-TPX2 complex, we determined the crystal structures of the 
AURKA catalytic domain in isolation or when liganded to AurkinA. Soaking of AurkinA into Mg2+-ATP-AURKA 
crystals yielded a liganded structure at 2.86 Å resolution (5DT4, Fig. 2, Supplementary Table 2). The electron den-
sity of AurkinA in the region of the pocket was well defined and its location and orientation was confirmed by an 
anomalous signal arising from the bromine atom at the meta position on the benzene ring (Fig. 2c, Supplementary 
Fig. 5). AurkinA was situated unambiguously in a hydrophobic pocket, lying in the groove formed by the α C and 
α B helices of the N-lobe (Fig. 2a). Comparison to the structure of AURKA in complex with TPX2 (Fig. 2b) 
demonstrated that this pocket accommodates both tyrosine residues within the YSY motif of TPX2, which has 
previously been shown to be crucial for the AURKA-TPX2 interaction10,11. We hereafter refer to this feature as the 
‘Y-pocket’. Analysis of AurkinA’s binding pose in the Y-pocket suggests that it formed hydrophobic interactions 
between its quinoline and phenyl motifs and the hydrophobic floor of the pocket created by L178, V182, V206 
and L208 (Fig. 2c). In addition, an ionic interaction was observed between the carboxylic acid of AurkinA and the 
basic side chain of K166. Of particular importance was the hydrophobic plug at the meta position of the benzene 
ring, which results in greater hydrophobic contact with the floor of the pocket. This observation was in line with 
the SAR data presented for the hydrophobic substituents at this position, demonstrating increased potency in the 
FA binding assay (Supplementary Table 1).
Interestingly, depending on the concentration of reducing agent in buffer, the AURKA kinase domain crystal-
lised either in space group P6122 or in P41212 (Supplementary Table 2). In P41212 crystals, grown under weakly 
reducing conditions, symmetry-equivalent C290 residues located on the activation loop formed an intermolec-
ular disulphide bridge. The structure-stabilising bridge resulted in a more rigid structure, enabling us to obtain 
higher resolution crystals. We obtained AurkinA-liganded AURKA catalytic domain in 2.05 Å resolution (5DN3) 
confirming that AurkinA adopts a near-identical binding pose in the Y-pocket (Supplementary Fig. 8). However, 
Figure 1. Identification of AurkinA, inhibitor of Aurora A-TPX2 complex. (a) The binding of AURKA123–403 
to TAMRA-TPX21–43 in fluorescence anisotropy assay. Kd = 83 nM (pKd = 7.07 ± 0.07). (b) Displacement of 
TAMRA-TPX21–43 by inhibitors in fluorescence anisotropy assay. (c) Synthetic strategy: deconstruction and 
optimisation of compound 1 identified from the HTS screen. Ki value was derived from FA competition assay 
using free-concentration corrected Cheng-Prusov equations49. Kd values were obtained using isothermal 
titration calorimetry. Ligand efficiency (Leff) was calculated using Ki or Kd values. Error bars represent standard 
deviation (n = 3).
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the intermolecular disulphide bridge and crystal contact in proximity to the Y-pocket rendered a constrained 
structure and thus we used the lower-resolution P6122 symmetry crystal (5DT4) to investigate conformational 
effects of ligand binding.
To further explore the structural characteristics of compounds that engage the Y-pocket of AURKA, we crys-
tallised two further compounds (AA29, AA30) obtained as hits from our analogue screen (Fig. 2f, Supplementary 
Table 1). The overlay of the crystal structures of AURKA liganded to AurkinA, AA29 and AA30 respectively, 
Figure 2. AurkinA triggers conformational changes in AURKA protein. (a) Crystal structure of AURKA126–390 
liganded with Mg2+ -ATP and AurkinA (5DT4,gray), overlayed with TPX21–43 (1OL538, orange). AurkinA 
(blue) is bound to the pocket defined by α C and α B helices, a binding site of the YSY motif of TPX2. The 
hydrophobic Y-pocket sits above the ATP-site. (b) The detail of AurkinA (blue) and TPX28–11 (orange) binding 
in the Y-pocket. (c) Binding pose of AurkinA in the Y-pocket. Carboxylic acid of AurkinA interacts with amine 
of K166, which is stabilised by H201. 2Fo-Fc map (blue) is countered at 1σ , anomalous map (pink) is contoured 
at 5σ . (d) The conformational change of Mg2+ -ATP liganded structure (5DT3, orange) upon AurkinA binding 
(5DT4, gray). The binding induces an anticlockwise rotation of α C helix by interacting with R179 and the 
hydrophobic floor. The shift of α B helix causes changes of hydrogen bonding pattern in glycine-rich loop, 
breaking of Q168-K143 hydrogen bond and movement of F144. (e) The overlay of AurkinA (magenta, 5DPV) 
and its analogues AA29 (green, 5DR9) and AA30 (cyan, 5DR6) bound to the Y-pocket. The related compounds 
bind with a consistent binding mode and the conformations of the amino acids lining the pocket are very 
similart between the liganded crystal structures. (f) The structures of the Y-pocket binders: AA29, AA30 and 
AurkinA; and JNJ-7706621, a potent ATP-competitive AURKA inhibitor.
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demonstrated their conserved binding mode in the Y-pocket (Fig. 2e). We found that the ATP-site binding com-
pound JNJ-7706621 stabilised the AURKA catalytic domain in solution (Supplementary Fig. 1c), and so we used 
it to assist the crystallisation process. We noted that whilst the structure for AA30, like that for AurkinA could 
be determined in complex with AURKA bound either to Mg2+-ATP or JNJ-7706621 in the active site, the AA29 
compound could only be soaked into AURKA complexed with JNJ-7706621. Overall, the phased anomalous elec-
tron density for the bromine atom in the AA29, AA30 and AurkinA was stronger in the crystals with JNJ-7706621 
(Supplementary Fig. 5).
AurkinA induces conformational changes in AURKA. Analysis of the AURKA structure in hexagonal 
crystals showed that it remained relatively unchanged when the ATP binding pocket was occupied either with 
ATP or with JNJ-7706621. In contrast, the binding of AurkinA, and indeed any of our compounds increased the 
overall B-factors of the crystal structures (Supplementary Fig. 7). Importantly, in all structures where a small mol-
ecule is bound in the Y-pocket, the electron density for the AURKA activation loop remained largely undefined.
More detailed analysis of the liganded crystal structures revealed that binding of AurkinA and its analogues 
caused significant local alterations to AURKA structure, as well as changes at sites distant from the Y-pocket 
(Fig. 2d). Firstly, the α C helix (residues E175-S186) moved up by ~1 Å as measured between Cα atoms of R180 
and R179 and was rotated anti-clockwise towards the N-terminal lobe. This resulted in formation of a π -cation 
interaction between the R179 side chain and AurkinA benzene ring, and a hydrophobic interaction between the 
L178 side chain and the quinoline moiety of AurkinA. The movement restricted the reach of R180, the residue 
that normally binds to phosphorylated T288 (pT288), as demonstrated by its inability to hydrogen bond with 
G276 in presence of the AurkinA. The R180-pT288 interaction is a key event in ordering of the activation loop, 
a first step towards the activation of the kinase12–15. Secondly, the binding of AurkinA in the Y-pocket caused an 
upward movement of helix α B (residues K166-A172, Fig. 2d). In turn, the α B helix shift introduced a movement 
in the ATP-binding glycine-rich (G-rich) loop, as signified by a shift of the residue F144 in presence of AurkinA. 
The hydrogen bond between Q168 on the α B-helix and the main chain carbonyl of K143 on the G-rich loop, 
observed consistently in the apo structures, was lost. In addition, a hydrogen bond between the backbones of F144 
and F165 was significantly shortened from 3.2 Å to 2.8 Å upon AurkinA binding. These detailed observations are 
consistent with the overall changes in the dynamics of the activation loop. It has been proposed that the α C and α 
B helices, as well as the G-rich loop form a conserved unit that regulates AURKA kinase activity16–18. Collectively, 
these structural changes suggest that AurkinA binding in the Y-pocket might allosterically modulate AURKA 
kinase activity.
AurkinA binding inhibits the kinase activity of AURKA in an ATP-independent manner. To 
test this hypothesis, we used a commercially available in vitro kinase assay (KinEASE, Cisbio) to measure 
AURKA-dependent phosphorylation of a generic peptide substrate by homogeneous time-resolved fluorescence 
(HTRF) assay (Supplementary Fig. 9). Enzymatic phosphorylation occurred in the presence of the substrate 
peptide and ATP, and the phosphorylated substrate was subsequently detected in a proprietary antibody detec-
tion step. These studies were performed using a T287/T288 doubly-phosphorylated recombinant AURKA126–390 
in the absence of TPX2. AurkinA treatment caused a dose-dependent inhibition of AURKA activity (Fig. 3a) and 
exhibited a low micromolar inhibitory constant (Ki = 3.7 μ M), which was in line with its Kd for the recombinant 
AURKA. Interestingly, binding of AurkinA to the Y-pocket did not completely inhibit kinase activity, but instead, 
levelled out at ~75% inhibition. This is in direct contract to the ATP-competitive inhibitor, MLN8237. The pres-
ence of residual activity even at excess inhibitor concentrations (25x Ki) raises the possibility that binding at the 
Y-pocket utilizes a distinct mode of AURKA kinase inhibition to ATP-competitive inhibitors, which achieve 
complete inhibition of the kinase.
We therefore carried out further kinetic experiments to determine the mechanism of ATPase activity inhi-
bition by AurkinA and similar allosteric inhibitors of AURKA. Based on our structural data, we hypothesised 
that the allosteric, Y-pocket-binding inhibitors would not affect the Km for ATP, as no significant changes in 
residues involved in ATP binding directly were observed upon AurkinA binding and ATP was always present in 
the active site. Instead, the structural data, which show changes in residues involved in ATP-ADP cycling and the 
activation loop ordering, suggested that the compound binding would alter the apparent turnover number of the 
enzyme (kcat) or its Km for substrate. Indeed, the enzyme kinetics experiments revealed that addition of AurkinA 
at different concentrations did not change the apparent Km for ATP while reducing Vmax (Fig. 3b), a hallmark of 
non-ATP competitive binding19–21. This reduction in Vmax is likely to incorporate the effect of compound binding 
on substrate affinity, since activation loop residues have been shown to interact with substrate in other kinases22,23. 
However, due to the assay’s intrinsic constraints on maximal usable substrate concentration, we were unable to 
fully separate the effects of compound on true catalytic turnover and Km of substrate.
To further analyse the effect of AurkinA on AURKA kinase activity, we developed an in vitro auto- 
phosphorylation assay. It has been extensively reported that auto-phosphorylation of Thr288 in the activation 
loop stimulates AURKA kinase activity24–26. We therefore generated a non-phosphorylated form of AURKA 
(AURKAGSMGS-126-390, see methods) and used this to monitor the auto-phosphorylation over time by Western 
blotting with anti-pT288 AURKA antibody in presence or absence of AurkinA. As shown in Fig. 3c, AurkinA 
significantly delayed the auto-phosphorylation of AURKA, demonstrating the ability of Y-pocket binding to 
reduce AURKA’s kinase activity towards at least one of its physiological substrates. Importantly, these TPX2-free 
kinase activity assays show that AurkinA inhibited AURKA activity not by preventing TPX2-dependent 
activation as would be expected from a protein-protein interaction inhibitor, but by induction of unexpected 
structural changes which impact directly upon kinase activity.
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In conclusion, the reduction of AURKA catalytic turnover is consistent with our structural data and provides 
a potential mechanistic link between Y-pocket binding and the inhibition of kinase activity.
AurkinA mislocalises AURKA in mitotic cells and inhibits AURKA kinase activity. Localisation of 
AURKA to the spindle during mitosis is dependent on binding to TPX227,28. Overexpression of the AURKA-interacting 
TPX2 peptide has been shown to cause mislocalisation of AURKA from spindle microtubules in Xenopus29,30 and 
human cells31,32. The same effect was observed when key residues (Y8, Y10, and D11) in TPX2 were mutated10,33 
or when an AURKA mutant (S155R) incapable of interacting with TPX2 was expressed50. In anticipation of 
observing this phenotype upon disruption of the AURKA-TPX2 interaction with a small molecule, we gener-
ated a HeLa cell line expressing inducible TPX21–43 mCherry fusion (hereafter referred to as mCherry-TPX21–43, 
Supplementary Methods). The cell line was validated by immunoprecipitation of mCherry-TPX21–43 and subse-
quent immunoblotting for AURKA, which confirmed interaction between the TPX2 peptide and the endogenous 
AURKA protein (Supplementary Fig. 10a). Confocal fluorescence microscopy revealed that upon induction of 
mCherry-TPX21–43, AURKA was mislocalised away from the spindle microtubules in mitotic cells (Fig. 4a). Based 
on this striking phenotype, we developed and validated an automated high-content microscopy assay with a Z’ of 
0.51 (see Materials and Methods) to measure AURKA mislocalisation from spindle microtubules.
Exposure of cells to AurkinA phenocopies the effect of mCherry-TPX21–43 expression, inducing mislocalisa-
tion of AURKA away from spindle microtubules in mitotic cells (Fig. 4a, bottom two panels). When this effect is 
quantified using the high-content assay described above, we observed a clear dose-dependent effect of AurkinA 
on AURKA localisation, with an EC50 of 85 μ M (Fig. 4b). At higher concentrations of the compound, AURKA was 
almost undetectable on the spindle. Moreover, neither AurkinA nor the mCherry-TPX21–43 affected the presence 
of AURKA at the centrosome (data not shown), which is in agreement with existing literature that TPX2 binding 
is not responsible for the centrosomal localisation of AURKA10.
Together, these observations provide strong evidence that AurkinA blocks the interaction between AURKA 
and TPX2 in cells. Since AurkinA can also inhibit AURKA kinase activity in vitro, we addressed the effect of the 
compound on AURKA kinase activity in cells by utilising a variation on the assay described above, measuring 
pT288 AURKA staining of the mitotic cells, instead of AURKA protein in general. Consistent with the in vitro 
assay results, AurkinA exposure causes a dose-dependent decrease in pT288-AURKA intensity (Fig. 4c). AurkinA 
therefore is able to both mislocalise AURKA, and inhibit its catalytic activity in cells.
Figure 3. AurkinA causes allosteric inihibition of the kinase activity of AURKA. (a) AurkinA inhibits 
the kinase activity of pT287/pT288 AURKA126–390 in homogeneous time-resolved fluorescence assay (HTRF, 
KinEASY, Cisbio) in absence of TPX2. The volume of enzymatic reaction was 10 μ L, [AURKA] = 5 ng/well, excess 
propriatory peptide substrate (1 μ M) and ATP (100 μ M). The reaction was incubated for 10 min. MLN8237 
is an ATP-competitive inhibitor used as a positive control. AurkinA excess did not cause a complete ablation 
of AURKA kinase activity. (b) In presence of AurkinA, the maximum rate of AURKA kinase activity (Vmax) 
decreased, but Km for ATP remained unchanged. Such a kinetic profile is consistent with a non-ATP competitive 
inhibition, suggesting that AurkinA inhibited the kinase activity of AURKA allosterically. (c) AurkinA slowed 
down the in vitro autophosphorylation of AURKAGSMGS-126-390 with uncleaved His-tag (30 μ M), as detected by 
anti-pT288 antibody. [ATP] = 100 μ M, J* = JNJ-7706621. Error bars represent standard deviation (n = 3).
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Discussion
Our findings demonstrate that AurkinA, a novel small-molecule inhibitor of the protein-protein interaction 
between the mitotic kinase AURKA, and the microtubule-associated protein, TPX2, inhibits AURKA locali-
zation and catalytic activity via an unexpected allosteric mechanism. AurkinA binds to AURKA primarily via 
interactions between its phenylquinoline core and the amino acid residues that line a hydrophobic pocket nor-
mally occupied by the Y8 and Y10 residues from TPX2 (the ‘Y-pocket’), with additional contributions from 
the meta phenyl hydrophobic plug and the polar interaction of the carboxylic acid moiety with the basic K166 
and H201 residues that form part of the pocket. Residues involved in ATP binding are relatively unaffected by 
AurkinA engagement, suggesting an unusual mechanism for allosteric inhibition of AURKA. Consistent with 
this mechanism, we find that AurkinA does not alter the apparent Km for ATP, although it reduces Vmax, fea-
tures compatible with the non-ATP competitive mode of binding observed by crystallography. In cells, AurkinA 
caused a dose-dependent mislocalisation of AURKA from the mitotic spindle, to which it is normally recruited by 
TPX2. Moreover, AurkinA caused a dose-dependent decrease in T288 autophosphorylation, a cellular biomarker 
of AURKA activity. Collectively, these findings not only reveal a previously unrecognized, critical role for the 
Y-pocket in regulating the catalytic mechanism of AURKA, but also define it as a target for a new class of selective 
small-molecule inhibitors that act dually to inhibit AURKA localization and catalysis in cells.
The implications of our findings for AURKA catalysis are best understood in the context of two TPX2-dependent 
switches recently proposed to regulate catalytic activity16. Switch-1, the residue K143 situated within the G-rich 
loop, may play an essential role in the kinetic cycle of ATP binding, ATP hydrolysis and ADP release, which is 
controlled not only through an interaction between K143 and ADP, but also by the modulation of ADP binding 
by the hydrogen bond network between the α B helix and the glycine-rich loop. In addition, Switch-2, R180 of 
the α C helix, is known to capture an autophosphorylated residue - pT288 - of the activation loop in the active 
configuration of AURKA.
A previously unrecognized role of the Y-pocket in regulating AURKA activity is revealed by our crystallo-
graphic data comparing allosteric changes in the AURKA catalytic domain induced by the TPX2 peptide versus 
AurkinA. While TPX2 and AurkinA both bind to the same hydrophobic site, they affect the two AURKA kinase 
activity switches, K143 and R180, in the opposite ways. In a comprehensive structural study of Aurora-A:TPX2 
interaction, Zorba et al.24 show the SYSYD moiety of TPX21–45 opens the Y-pocket of inactive, dephosphorylated 
Aurora-A and forces the α C-helix to rotate clockwise (N to C). The rotation affects the position of R180 and 
makes it available for pT288 binding, which stabilises the activation loop, thereby increasing ATPase activity. 
Figure 4. AurkinA mislocalises AURKA from the bipolar spindle in mitotic cells. (a) Representative 
immunofluorescence images of HeLa cells expressing mCherry-TPX21–43 fusion protein under doxycycline 
(DOX) control. mCherry-TPX21–43 fusion overexpression as well as AurkinA mislocalise of AURKA from 
the spindle. (b) Quantitative analysis of AURKA mislocalisation from the spindle, as defined by % cells with 
below threshold AURKA intensity under TPX2 mask. AurkinA mislocalises AURKA from the spindle in a 
dose dependent manner with EC50 = 85 μ M. (c) AurkinA deactivates AURKA, as measured by increase of % 
of cells with below threshold phosohorylated T288 (pT288). EC50 = 135 μ M. The error bars represent standard 
deviation (n = 5).
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Similarly, α B-helix is affected by TPX2 binding, resulting in the formation of a hydrogen bond between K143 
of the ATP-binding, G-rich loop and E168. It has been suggested that this hydrogen bond facilitates the release 
of ADP from the ATP site by lifting the glycine-rich loop; indeed, we found it present in a number of structures 
of AURKA in the active conformation. The binding of the flat Y-pocket binders, exemplified by AurkinA, did 
not mimic the TPX2, but instead affected the AURKA switches in opposite ways. AurkinA binding caused the 
α C-helix to twist anticlockwise, which resulted in upwards movement of R180, restricting its range. Similarly, the 
hydrogen bonding interaction pattern between α B helix and G-rich loop was altered upon AurkinA binding. The 
F165-F144 backbone hydrogen bond was significantly shortened (3.2 Å to 2.8 Å) and the K143-Q168 hydrogen 
bond present in the ‘active’ apo structure was broken in the presence of the Y-pocket binders, potentially impair-
ing the ADP removal from the ATP-site (see Supplementary Video 1). Taken together, these results demonstrate 
the crucial role of the α C-helix and the glycine-rich loop residues in the regulation of AURKA catalysis, and 
demonstrate the structural mechanism by which Y-pocket engagement by AurkinA allosterically modulates the 
kinase.
Importantly, our work also exemplifies a new approach for targeting AURKA and structurally related kinases 
for chemical biology or therapeutics development. AURKA shares with closely related AGC family kinases a high 
degree of structural similarity in the vicinity of the Y-pocket. Of note, PDK1 binds to its regulatory factor PIF 
using an analogous pocket (also called the ‘PIF pocket’), and several other therapeutically relevant AGC kinases 
(including the CMGC, TK or other families) also possess a Y- or PIF pocket. Thus, our studies not only add to 
the growing evidence that the catalytic activity of AGC family kinases can be modulated by small-molecule lig-
ands that engage the Y- (or PIF) pocket, but also suggest that the approach we have taken may be more generally 
applicable.
Methods
Expression and purification of human Aurora-A kinase. All AURKA constructs (as described in 
Supplementary Methods) apart from AURKA123–403 were expressed in BL21 (DE3) cells containing pUBS550 
plasmid cultured in 2xYT media supplemented with ampicillin (100 mg mL−1) and kanamycin (25 mg mL−1). 
Bacteria were grown at 37 °C until an OD600 of 0.5–0.6 when the temperature was lowered to 18 °C for 1 h before 
induction with IPTG (0.4 mM). Protein was expressed overnight at 18 °C and bacteria were harvested by cen-
trifugation and pellets frozen in − 80 °C. Thawn cells were resuspended to 5 mL/g final concentration in buffer 
A (50 mM Tris-HCl pH 8.0, 500 mM NaCl, 100 mM Mg(OAc)2, 1 mM ATP, 1 mM DTT, 40 mM imidazole) and 
lysed using Emulsiflex homogeniser. Lysate was cleared by centrifugation at 30000 × g at 4 °C for 30 minutes. 
Clarified lysate was loaded onto a HisTrap HP column (5 ml, GE Healthcare), washed with buffer A and eluted 
by buffer B (50 mM Tris-HCl pH 8.0, 500 mM NaCl, 100 mM Mg(OAc)2, 1 mM ATP, 1 mM MgCl2, 1 mM DTT, 
600 mM imidazole). The N-terminal His-tag on the Aurora-AGSMGS-126-391 construct was cleaved off by incubation 
with His-tagged TEV protease at the molar ratio 1:30 and simultaneously dialysed against buffer A at 4 °C over 
night. Cleaved protein was loaded onto a 5 ml HisTrap HP column and eluted using a gradient of 40 to 120 mM 
imidazole. Eluted protein was gel filtered using HiLoad Superdex 75 16/60 column (GE Healthcare) equilibrated 
with buffer C (50 mM HEPES pH 7.4, 50 mM NaCl, 100 mM Mg(OAc)2, 1 mM ATP, 1 mM MgCl2, 1 mM DTT). 
Peak fractions were pooled, concentrated to 7 mg mL−1 and flash frozen in liquid nitrogen for storage at − 80 °C. 
Protein concentration was determined by UV absorption at 280 nM using NanoDrop 1000 spectrophotometer 
(Thermo Scientific).
His-tagged AURKA123–403 construct was expressed by autoinduction in freshly transformed BL21 (DE3) cells 
with the pBAD plasmid. Starter cultures were initiated in LB broth supplemented with ampicillin (100 μ g mL−1) 
and glucose (2%). After 4–6 h, large-scale ZYM-5052 cultures were inoculated from the starter cultures and 
incubated for 3 h at 37 °C followed by 16–18 h at 20 °C with 250–300 rpm shaking. The cells were harvested by 
centrifugation and pellets frozen in − 80 °C. All following work was carried out at 4 °C. The pelleted cells were 
resuspended in binding buffer (50 mM Tris, pH 8.0; 40 mM imidazole, 500 mM NaCl, 5 mM MgCl2, 10% glycerol, 
5 mM beta-mercaptoethanol, protease inhibitors) and lysed using Emulsiflex homogeniser. Lysate was cleared by 
centrifugation at 30000 × g for 45 min. The supernatant was loaded to equilibrated 2xHisTrapFF 5 mL colums at 
rate 0.3 ml/min column by Akta Purifier overnight, washed with wash buffer (50 mM Tris, pH 8.0, 40 mM imida-
zole, 1 M NaCl, 5 mM MgCl2, 10% glycerol, 5 mM beta-mercaptoethanol) and eluted with elution buffer (50 mM 
Tris-HCl, pH 8.0, 270 mM imidazole, 750 mM NaCl, 5 mM MgCl2, 10% glycerol, 5 mM beta-mercaptoethanol). 
The eluted protein was concentrated to 2.5 ml using a Vivaspin 20 (Sartorius) concentrator and buffer was 
exchanged to (20 mM Tris-HCl, pH 8.0, 500 mM NaCl, 5 mM MgCl2, 10% glycerol, 1 mM dithiothreitol) using 
PD10 column. The protein was further concentrated to 1 mL and loaded onto HiLoad 75 or 200 Superdex 16/60 
column using Akta Purifier at 0.2 mL/min. Peak fractions were pooled, concentrated to 10 mg mL−1 and flash 
frozen in liquid nitrogen for storage at − 80 °C.
Isothermal Titration Calorimetry. Calorimetric titrations were performed on an iTC200 (MicroCal, Inc.) 
device. Protein was buffer exchanged into ITC buffer (Buffer C with 2% DMSO). Titration experiments were per-
formed at 25 °C with an initial injection (0.4 μ L) at a duration of 0.8 s, followed by 19 injections (2 μ L) at a duration 
of 4 s. For the binding assays, compound 1 (600 μ M) or AurkinA (300 μ M) or was titrated into Aurora-AG-126-390 
protein solution (30 μ M). The spacing between injections was 180 sec and 300 sec for compound 1 and AurkinA, 
respectively. For the ITC experiments with compound 1 the correction for the heat of dilution was carried out by 
subtracting the average value of the last three data points of the titration. Correction for the enthalpy of dilution 
for the experiments with compound AurkinA was carried out by subtracting of blank injection heats obtained 
by the titration of the compound AurkinA solution into the ITC buffer. Binding isotherms were fit by non-linear 
regression using the single-site model provided by Origin software (MicroCal, Inc.). The stoichiometry of the 
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interaction (N), equilibrium association constant (Ka) and change of enthalpy (Δ H) were floated during the 
fitting.
Auto-phosphorylation experiments. For autophosphorylation experiments Aurora-A kinase construct 
AurAGSMGS-126-391 was purified as described above but using buffers containing no ATP and His-tag was left on the 
N-terminus. To start the auto-phosphorylation reaction, ATP (100 μ M) was added to the Aurora-A kinase sam-
ples in assay buffer (50 mM HEPES pH 7.4, 150 mM NaCl, 1 mM MgCl2, 1 mM DTT) at final protein concentra-
tion of 30 μ M and incubated for up to 40 min. at room temperature in presence or absence of AurkinA (100 μ M). 
10 μ L samples were taken 0, 5, 10, 15, 20 and 40 min. after adding ATP. The reaction was stopped by the addition 
of 10 μ L 2× SDS-PAGE sample loading buffer. Control sample contained JNJ-7706621 (100 μ M) that was added 
to the reaction prior ATP. 15 ng of each sample were run in 11% SDS-PAGE gels.
Western blot analysis. Western blots were prepared by electro-blotting SDS-PAGE gels onto PVDF 
membranes (Millipore) and probing with anti-penta-his-tag antibody (1:2000 dilution, Qiagen, 34660) or 
anti-Aurora-A phosphoT288 antibodies (1:1000 dilution, Abcam, ab195748), followed by HRP conjugated 
TLCtmâ sheep anti-mouse antibodies (GE Healthcare) or HRP conjugated goat anti-rabbit antibodies (Abcam), 
respectively.
Crystallisation and data collection. Aurora-A crystals were grown by hanging-drop vapour diffusion 
at 19 °C in crystallization buffer (100 mM HEPES pH 7.0, 200 mM MgSO4, 5–20% PEG3350). Crystals were 
cryoprotected in mother liquor supplemented with glycerol (20%) and DMSO (1–10%) and cryo-cooled in liquid 
nitrogen. For crystal-soaking experiments crystals were incubated over night at 19 °C in cryoprotecting solution 
supplemented with compound (1 mM).
Diffraction data were collected on beamlines i04–1, i02 and i03 at the Diamond Light Source  (Harwell, UK) 
and Proxima 1 beamline at SOLEIL synchrotron (Saint Aubin, France) and were processed using Pipedream 
(Global Phasing Limited, A. Sharff, P. Keller). Data for crystals containing brominated compounds were col-
lected at the wavelength near the bromine absorption edge (13500 eV) to maximise the anomalous signal. Manual 
rebuilding and model refinement was performed with COOT51, REFMAC52 and BUSTER53. Molecular topology 
was generated using PRODRG2 Server54 and the anomalous difference Fourier maps were generated using FFT55. 
Positive electron density peaks in the anomalous maps were used for unambiguous identification of the bromine 
compound location and binding stoichiometry. Molecular graphics images and “Morph movies” were produced 
using UCSF Chimera package56.
Immunoblotting and co-immunoprecipitation. Stable HeLa FlpIn TREx cell line expressing a fusion 
mCherry-TPX21–43 protein upon addition of doxycycline (0.5 mg ml−1) was generated (Supplementary Methods). 
This cell line was used for further experiments. For immunoblotting, proteins were extracted in lysis buffer 
(50 mM HEPES, pH 7.4; 100 mM NaCl, 0.5% NP-40, 10 mM EDTA, 20 mM β-glycerophosphate, 1 mM DTT, 
1 mM sodium orthovanadate, 1 mM PMSF, protease inhibitors and phosphatase inhibitor (Roche)). 0.5 mg of 
lysate was used for co-immunoprecipitation. mCherry pull down was performed using RFP-trap (Chromotrap) 
following manufacturers’ instructions. Extracts were resolved by SDS-PAGE, transferred to PVDF membrane, 
blocked in TBS-Tween (50 mM Tris pH 7.6, 150 mM NaCl, 0.1% Tween-20) plus 5% non-fat dried milk, and 
probed with primary antibodies at 4 °C overnight. Membrane was incubated with secondary mouse HRP 
(GE Healthcare, NXA931) and rabbit HRP antibodies (Jackson Laboratories, 111-036-047) for 1 h at room tem-
perature and the signal was developed using ECL or ECL prime reagent (GE Healthcare).
Immunofluorescence (IF) and confocal microscopy. For confocal imaging, cells were grown on glass 
coverslips with appropriate treatments, fixed with ice-cold methanol for 10 min. Cells were permeabilised with 
0.1% Triton-100 (Fischer), 0.1% Tween-20 (NBS Biologicals) in 1x PBS (PBS-Triton-Tween) for 10 min and 
blocked with 3% BSA (Fischer Scientific) in PBS-Triton-Tween for 30 min. The samples were incubated with 
antibodies: Aurora-A (1:1000) and TPX2 (Abcam 18D5–1, 1:500) diluted in blocking solution for 1 h at room 
temperature in humidified chamber. These was washed thrice in blocking solution, and incubated with Alexa 
Fluor- conjuagated secondary antibodies (Life Technologies) in dark for 30 min. Samples were washed with 
blocking solution, stained in Hoechst 33342, mounted in VectaShieldTM and stored in dark at 4 °C before micros-
copy. The images were captured using Leica SP5 confocal microscope using a 100 × 1.4 NA oil objective with 
z-stacks taken at 1 μ m intervals. Pixel intensities were never saturated and laser exposure and detector settings 
were identical across an experiment to allow comparison between samples.
IF staining, high-content microscopy and analysis. For identification of a single clone suitably 
expressing mCherry-TPX2 upon induction with doxycycline and low background in uninduced condition, 
the cells in 96-well plates were replica plated and grown in doxycycline (0.5 mg ml−1) containing medium for 
24 h, fixed in formaldehyde (4%, v/v), stained for nuclei with Hoechst 33342 (4 mg ml−1) and imaged using 
high-content microscope - Cellomics ArrayScanTM (ThermoFischer) and the intensity of mCherry expression 
was assessed using its Target Activation protocol.
For quantitative determination of Aurora-A mislocalisation from spindle microtubules, cells were plated at 
a density of 0.75 × 105 cells per well of a clear flat bottom 96-well plate. On each plate a set of wells were treated 
with doxycycline as a positive control. After 24 h the compounds were diluted in 10 mM Bortezomib (Selleck 
Chemicals) and treated for 2 h. Hereafter all steps were carried out at room temperature. The cells were fixed by 
addition of freshly prepared PHEM-buffered formaldehyde (100 μ L per well) for 10 minutes (100 mM PIPES, 
20 mM HEPES, 5 mM EGTA, 2 mM MgCl2, 0.2% TritonX-100, 6.4% formaldehyde). These were permeablised 
with 100 μ l of PBS-T-T (1X PBS/0.1% Triton- 100/0.1% Tween-20) for 10 min, blocked in 3% BSA-PBS-T-T for 
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30 min. Hereafter all the steps including dilution of antibodies was done in the blocking solution. A cocktail 
of primary antibodies (50 μ L, mouse anti-TPX2, Abcam 32795, 18D5-1, 1:500; rabbit anti-Aurora A, Millipore 
EP1008Y, 1:1000) for 1.5 h and washed thrice with the blocking solution. A cocktail of secondary antibodies (50 μ L, 
goat Alexa Fluor 633 anti-mouse IgG, Life Technologies, A21052, 1:500; goat Alexa Fluor 488 anti-rabbit IgG, 
Invitrogen, A11034, 1:500) and incubated for 30 min in dark. The cells were washed and the DNA was stained by 
Hoechst 33342 (4 μ g ml−1) in 1X PBS. Removed excess stain by washing twice with 1X PBS and added 100 μ L 1X 
PBS. Plates were stored at 4 °C in dark before scanning on Cellomics ArrayScan (ThermoFischer).
The plates were scanned using Molecular Translocation protocol with 40X objective with 3 flurophore rec-
ognising channels. Channel 1 was used to identify Hoeschst-stained nuclei as primary objects, channel 2 was 
used to identify TPX2-stained spindles in mitotic cells amongst valid channel 1 objects, and channel 3 was used 
to identify Aurora-A staining in valid channel 2 objects. The software generated an overlay of TPX2-stained 
spindles (channel 2), and the average intensity of the Aurora-A (channel 3) within that mask was scored. After 
the plates were scanned, the data was exported into Excel and the highest Aurora-A intensity in the darkest 10% 
of untreated samples was used to set a threshold below which Aurora-A was classified as delocalised. Once the 
threshold was applied, the percentage of cells with Aurora-A intensity in the TPX2 mask below the threshold was 
reported as percentage of cells with mislocalised AURKA.
High-content AURKA T288-dephosphorylation assay. A modified version of the Aurora A mislo-
calisation assay using the same cells, doxycycline-treated controls, drugging plan, Bortezomib treatment, fixing 
protocol, Hoechst staining and secondary antibodies as above. The primary antibodies used were anti-phospho 
Aurora A Thr288 (Cell Signaling, #3079, 1:500) and anti-Histone H3 phospho S10 (Abcam, 14955, 1:2000). 
High-content imaging settings were the same as for the mislocalisation assay, but analysis was performed using 
the CellHealthProfiling v4 Bioapplication. Cells were identified in the Hoechst channel as above, and the resulting 
nuclear mask used for all subsequent measurements. Mitotic cells were selected from the images on the basis of 
phospho-histone H3 positivity, using a threshold 10 times above the image background. These selected cells were 
then measured for phospho-Aurora A staining intensity within a target area defined by expanding the nuclear 
mask by 8 pixels then collapsing it using a threshold for the phospho-Aurora channel, set to 3 times the back-
ground staining in this channel. Assay thresholds were calculated from the negative control wells of each plate as 
for the mislocalisation assay and ‘% dephosphorylated Aurora A T288’ scores were calculated for each well. EC50 
values were calculated from four-parameter dose-response curves that were fitted using Prism GraphPad software 
(La Jolla, CA).
Synthesis of 2-(3-bromophenyl)-8-fluoroquinoline-4-carboxylic acid (AurkinA). 7-fluoroisatin 
(165 mg, 1.00 mmol), 3-bromoacetophenone (0.16 mL, 1.2 mmol) and KOH (168 mg, 8.27 mmol) were dissolved 
in EtOH (2 mL). The reaction mixture was heated sealed tube in microwave for 1 h at 120 °C and the solvent was 
removed in under reduced pressure. The residue was dissolved in H2O and washed with equal volume of Et2O 
twice. The aqueous layer was cooled to 0 °C, acidified to pH 2 with HCl (conc.) and the precipitate was collected as 
a crude product which was subsequently recrystallised from 30% EtOH in H2O to yield the pure product (22 mg, 
10%). 1H NMR (500 MHz; DMSO-d6): δ 14.18 (s, 1H), 8.58 (s, 1H), 8.51 (d, J = 0.8 Hz, 1H), 8.46–8.43 (m, 1H), 
8.33 (d, J = 7.8 Hz, 1H), 7.76 (dt, J = 8.0, 1.0 Hz, 1H), 7.72 (t, J = 6.6 Hz, 2H), 7.56 (t, J = 7.9 Hz, 1H); 13C NMR 
(126 MHz; DMSO-d6): δ 167.2, 157.4 (d, J = 255.2 Hz), 154.4, 139.8, 138.4 (d, J = 11.6 Hz), 138.1, 133.0, 131.2, 
129.8, 128.1, 126.4, 125.2, 122.5, 121.4, 120.1, 114.5 (d, J = 18.2 Hz); IR (solid) ν max 3200–2650 (O-Hacid, broad), 
1697 (C=Oacid, sharp), 1587 (C=Caromatic, sharp), cm−1; HRMS (m/z): [M-H]+ calculated for C16H10BrFNO2, 
345.9879; found 345.9903.
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